Please try another search
For the six months ended 30 June 2019, Bellerophon Therapeutics Inc revenues was not reported. Net loss decreased 34% to $4.9M. Lower net loss reflects Research and development decrease of 63% to $4.4M (expense), General and administrative decrease of 13% to $2.6M (expense), Stock-based Compensation in General decrease of 12% to $1.1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.13 to -$0.07.
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -4.22 | -4.34 | -4.68 | -6.83 |
Net Income | -4.11 | -0.8 | -0.91 | 11.1 |
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Total Assets | 20.58 | 24.79 | 18.36 | 23.64 |
Total Liabilities | 9.12 | 14.49 | 14.5 | 19.71 |
Total Equity | 11.46 | 10.3 | 3.86 | 3.93 |
Period Ending: | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -6.08 | -2.34 | -15.49 | -11.44 |
Cash From Investing Activities | 0 | 3 | 2 | |
Cash From Financing Activities | 6.24 | 6.37 | 0.17 | 0.17 |
Net Change in Cash | 0.15 | 4.03 | -12.33 | -9.27 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review